Emergent BioSolutions Share Price - EBS, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information(NYSE:EBS, EBS)

Emergent BioSolutions
www.emergentbiosolutions.com

Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease.

News

28/12/11
Emergent announces termination of Abbott collaboration for TRU-016 drug
01/12/11
Emergent BioSolutions gets orphan drug status for potential cancer treatment
06/06/11
Emergent BioSolutions acquires rights to lymphoma drug from TenX BioPharma
04/11/10
Emergent BioSolutions' inhalation anthrax treatment receives orphan drug status
01/10/10
Emergent BioSolutions Receives Fast Track Status for Inhalational Anthrax Drug Program
08/09/10
Emergent BioSolutions Begins Phase I Trial for Inhalational Anthrax Treatment Drug

All Emergent BioSolutions News ►

Recent Sector News

Dow seen opening higher ahead of jobless data, Facebook, Hewlett-Packard in focus

U.S. equity markets looked set to point to open higher Thursday after strong earnings from Hewlett-Packard (NYSE:HPQ), and as talks progress on Greece's debt crisis.
Dow suffers on Greece fears, Hewlett-Packard in focus

U.S. equity markets fell Wednesday afternoon on concerns that Greece could exit the euro as the region’s gather for an informal meeting.
Dow points lower ahead of eurozone meeting, Facebook, Dell in focus

U.S. equity markets looked set to open lower Wednesday morning ahead of a meeting of European Union leaders amid continued worries over the eurozone debt crisis.
Q1 gold demand underpinned by China, Central Banks and ETFs

Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up

Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
Facebook boosts public offering by 25%

Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.